Information Provided By:
Fly News Breaks for February 21, 2019
GHDX
Feb 21, 2019 | 08:48 EDT
Needham analyst Stephen Unger raised his price target on Genomic Health to $97 and kept his Strong Buy rating after its Q4 results and higher than expected FY19 earnings guidance. The analyst notes that the company's financial model offers "significant operating leverage" that was "clearly demonstrated" in 2018 and sees potential for earnings growth to persist this year thanks to the better than expected testing volumes of its Oncotype breast cancer test product.
News For GHDX From the Last 2 Days
There are no results for your query GHDX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.